Accueil › Myélome multiple › Massachusetts › Boston
Essais cliniques pour Myélome multiple à Boston, MA
42 études pour Myélome multiple recherchent des participants dans et autour de Boston (dans un rayon d'environ 30 miles). Ouvrez une étude pour voir qui peut participer et comment contacter l'équipe.
Texte officiel de l'étude (anglais)
Vous recrutez pour une étude ? Mettez-la en avant en haut de cette page — $99 pour 30 jours →
A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)
Recrutement en coursPhase 3
- Research Site, Boston
- Research Site, Boston
A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
Recrutement en coursPhase 3
- Tufts Medical Center, Boston
A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
Recrutement en coursPhase 3
- Dana Farber Cancer Institute, Boston
- Boston University Medical Center, Boston
A Study to Compare Linvoseltamab and Daratumumab Treatment in High-Risk Smoldering Multiple Myeloma (HR-SMM)
Recrutement en coursPhase 3
- Dana Farber / Harvard Cancer Center, Boston
A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel
Recrutement en coursPhase 4
- Dana Farber Cancer Institute, Boston
- Beth Israel Deaconess Medical Center, Boston
- Massachusetts General Hospital, Boston
A Study of mRNA-2808 in Participants With Relapsed or Refractory Multiple Myeloma
Recrutement en coursPhase 1/2
- Mass General Brigham, Boston
Study of Belantamab Mafodotin With Carfilzomib, Pomalidomide, and Dexamethasone in Relapsed Multiple Myeloma
Recrutement en coursPhase 2
- Beth Israel Deaconess Medical Center, Boston
ELISA in Relapsed/Refractory MM
Recrutement en coursPhase 2
- Massachusetts General Hospital, Boston
- Beth Israel Deaconess Medical Center, Boston
- Dana Farber Cancer Institute, Boston
A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)
Recrutement en coursPhase 3
- Boston Medical Center, Boston
Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma
Recrutement en coursPhase 2
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)
Recrutement en coursPhase 1/2
- Dana-Farber Cancer Institute /ID# 271846, Boston
Elranatamab in R/R Multiple Myeloma
Recrutement en coursPhase 2
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
- Beth-Israel Deaconess Medical Center, Boston
Study of SIM0500 Alone in Participants With Relapsed or Refractory Multiple Myeloma
Recrutement en coursPhase 1
- Dana Farber Cancer institution, Boston
A Study to Evaluate a Novel Gene Therapy in Patients With Relapsed and Refractory Multiple Myeloma
Recrutement en coursPhase 1
- Massachusetts General Hospital, Boston
MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
Recrutement en coursPhase 3
- Beth Israel Deaconess Medical Center, Boston
- BIDMC Research Pharmacy, Boston
A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments
Recrutement en coursPhase 1/2
- GSK Investigational Site, Boston
AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Multiple Myeloma
Recrutement en coursPhase 1/2
- Research Site, Boston
Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial
Recrutement en coursPhase 3
- Tufts Medical Center, Boston
A Trial to Learn if Linvoseltamab is Safe and Works in Adults With Relapsed or Refractory Systemic Light Chain Amyloidosis (AL Amyloidosis)
Recrutement en coursPhase 1/2
- Boston Medical Center, Boston
A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma
Recrutement en coursPhase 1
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
Systemic Anti-Cancer Therapy Dose Modifications for Individuals With Duffy Null Phenotype
Recrutement en coursPhase 1
- Dana-Farber Cancer Institute, Boston
AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)
Recrutement en coursPhase 1/2
- Research Site, Boston
- Research Site, Boston
Immuno-PRISM (PRecision Intervention Smoldering Myeloma)
Recrutement en coursPhase 2
- Dana Farber Cancer Institute, Boston
A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of Arlocabtagene Autoleucel (BMS-986393) in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma
Recrutement en coursPhase 1
- Beth Israel Deaconess Medical Center, Boston
- Dana-Farber Cancer Institute, Boston
Selinexor and Backbone Treatments of Multiple Myeloma Patients
Recrutement en coursPhase 1/2
- Dana Farber Cancer Institute, Boston
A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Participants With Multiple Myeloma That is Resistant to Current Standard of Care Treatments
Recrutement en coursPhase 1
- Dana Farber/Harvard Cancer Center, Boston
Low-Dose Radiotherapy in Treating Painful Bone Metastases in Patients With Multiple Myeloma
Recrutement en cours
- Dana-Farber Cancer Institute, Boston
Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
Recrutement en coursPhase 3
- Tufts Medical Center, Boston
- Beth Israel Deaconess Medical Center, Boston
Study to Assess Safety and Tolerability of OPN-6602 in Subjects With Relapsed and/or Refractory Multiple Myeloma
Recrutement en coursPhase 1
- Dana Farber Cancer Institute, Boston
DC/MM Fusion Vaccine With BCMA CAR-T in R/R MM
Recrutement en coursPhase 1
- Beth Israel Deaconess Medical Center, Boston
A Phase 1 Study of Vaccination With Dendritic Cell (DC)/Multiple Myeloma (MM) Fusions in Combination With Elranatamab in Relapsed or Refractory Multiple Myeloma
Recrutement en coursPhase 1
- Beth Israel Deaconess Medical Center, Boston
- Dana-Farber Cancer Institute, Boston
Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.
Recrutement en coursPhase 1
- Dana Farber Cancer Institute, Boston
Defining the Role of Palliative carE for Patients With Hematologic Malignancies Undergoing Adoptive CEllular Therapy
Recrutement en cours
- Massachusetts General Hospital Cancer Center, Boston
Mezigdomide and Talquetamab in Relapsed and Refractory Multiple Myeloma
Recrutement en coursPhase 1
- Massachusetts General Hospital, Boston
- Beth Israel Deaconess Medical Center, Boston
- Dana-Farber Cancer Institute, Boston
Study of ISB 2001 in Relapsed/Refractory Multiple Myeloma (TRIgnite-1)
Recrutement en coursPhase 1
- Beth Israel Deaconess Medical Center, Boston
A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
Recrutement en coursPhase 1/2
- Massachusetts General Hospital, Boston
A Study to Assess BMS-986453 in Participants With Relapsed and/or Refractory Multiple Myeloma
Recrutement en coursPhase 1
- Dana-Farber Cancer Institute, Boston
Prehabilitation Exercise Training in Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation
Recrutement en cours
- Dana Farber Cancer Institute, Boston
- Dana-Farber Cancer Institute, Boston
Isatuximab, Bela Maf, Pom, and Dex in Relapsed/Refractory Multiple Myeloma
Recrutement en coursPhase 2
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
Elotuzumab + Iberdomide + Dexamethasone Post Ide-Cel in RRMM
Recrutement en coursPhase 1/2
- Brigham and Women's Hospital, Boston
- Beth Israel Deaconess Medical Center, Boston
- Dana Farber Cancer Institute, Boston
Collection of Samples and Clinical Data From Patients With Amyloid Diseases
Recrutement en coursÉtude observationnelle
- Boston University Cancer Research Center, Boston
A Study to Evaluate Safety, Drug Levels and Effectiveness of CC-92480 (BMS-986348) in Combination With Other Treatments in Participants With Relapsed or Refractory Multiple Myeloma
Recrutement en coursPhase 1/2
- Dana-Farber Cancer Institute, Boston
Essais pour Myélome multiple dans d'autres villes
- New York City, NY60 études
- Atlanta, GA41 études
- Houston, TX38 études
- Durham, NC37 études
- Nashville, TN32 études
- Denver, CO27 études
- Rochester, MN24 études
- St. Louis, MO24 études
- Columbus, OH24 études
- Baldwin Park, CA23 études
- Chicago, IL22 études
- Seattle, WA22 études
Autres études à Boston
- Cancer du sein111 études
- Cancer du poumon non à petites cellules90 études
- Cancer (tous types)86 études
- Cancer colorectal63 études
- Cancer métastatique63 études
- Cancer du poumon62 études
- Cancer de l'ovaire61 études
- Cancer de la prostate59 études
- Dépression52 études
- Cancer de l'endomètre50 études
- Insuffisance cardiaque44 études
- Leucémie aiguë myéloïde44 études
Source : ClinicalTrials.gov, données récupérées le 5 oct. 2026. Chaque étude définit ses propres critères d'éligibilité ; l'équipe de l'étude décide qui peut y participer.